ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VLG Venture Life Group Plc

36.75
0.00 (0.00%)
Last Updated: 08:00:23
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Venture Life Group Plc LSE:VLG London Ordinary Share GB00BFPM8908 ORD 0.3P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 36.75 36.00 37.50 36.75 36.75 36.75 64,272 08:00:23
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Misc Retail Stores, Nec 43.98M 520k 0.0041 89.63 46.24M
Venture Life Group Plc is listed in the Misc Retail Stores sector of the London Stock Exchange with ticker VLG. The last closing price for Venture Life was 36.75p. Over the last year, Venture Life shares have traded in a share price range of 27.00p to 44.00p.

Venture Life currently has 125,831,530 shares in issue. The market capitalisation of Venture Life is £46.24 million. Venture Life has a price to earnings ratio (PE ratio) of 89.63.

Venture Life Share Discussion Threads

Showing 23576 to 23596 of 36675 messages
Chat Pages: Latest  951  950  949  948  947  946  945  944  943  942  941  940  Older
DateSubjectAuthorDiscuss
09/1/2019
08:27
Blimey see what you mean Jane.Definitely some signs of life in the market more broadly.
hydrus
09/1/2019
08:25
something odd at prsm today; no idea what yet : trading now resumed. most odd
janeann
09/1/2019
07:49
Another materially ahead statement, this time at SCT - share price fall from September seems overdone.
valhamos
08/1/2019
23:07
I dont know Red
We're not out of the woods yet.. Might be able to buy them back a lot cheaper.
But then again who knows these days!!

P.s getting board of the guessing through the instability.
might switch off till its decided if its the union flag or the blue one with gold stars flying over the tower :)

thelongandtheshortandthetall
08/1/2019
20:28
Bloomberg
‏@business
Follow Follow @business
More

'Growth in Mercedes car deliveries tumbled to the lowest in a decade last year.'

Looks my friend from new years eve was spot on.
best to avoid car sales co's. for the time being.

But if your in the market for a new car then you'll probably get a bargain if you squeeze a little.

thelongandtheshortandthetall
08/1/2019
17:55
Been falling all my life, tlst.
The consequence of 'punching above your weight' is that you get floored!
apad😡

apad
08/1/2019
17:11
Think the £ is going to fall for a couple of days.
Yes its probably obvious.. :)

thelongandtheshortandthetall
08/1/2019
13:33
"Sometimes I wish I could lock down certain shares on my SIPP, those that I've decided to be a VLTH in and wish to hide away and forget - experience shows that's sometimes the best way to invest in them, and lose out on trying to trade in them."

Couldn't agree more, it's the core of my investment policy.
The problem is that the number of stars are limited and that they do sometimes fall of their perch.
So, one cannot be completely hands-off. I check out HLMA on their FY, in a pretty cursory fashion. It's enough and I don't expect to sell them ever.
ABC looked to be similar but there is clear evidence that they have mismanaged their software development, so I now look more closely.
I went from ICI to Zeneca to Astra Zeneca and the story is clearly very different now, from when ICI was a stalwart.
The past doesn't predict the future, but good business models exercised by powerful companies can last for a long time.

apad

apad
08/1/2019
13:27
The impression I get from another very small non listed company but very similar in how it works to arc is that money is fairly tight at present and new business isnt being one easily because of the wider market jutters/brexit etc.

But in time new business should come arcs way and it will be diofficult to buy onany announcement. A few small trades also triggers a bit of a spike from which the share price reverts back to previous level. Not that I am keen to trade arc either

janeann
08/1/2019
13:15
ARC - think all's very clear at the moment. Will keep ear to the ground, but ARC's a very quiet company.

Sometimes I wish I could lock down certain shares on my SIPP, those that I've decided to be a VLTH in and wish to hide away and forget - experience shows that's sometimes the best way to invest in them, and lose out on trying to trade in them. In other words, am own worse enemy sometimes.

cooltools
08/1/2019
12:59
OT) Please look at Futura Medical (FUM) has a dirt low market cap of 19 Million and has 3 Drugs including a potential MEGA Blockbuster in Phase 3 for the treatment of erectile dysfunction which works way faster than market leaders like Viarga and Cialis . If you look for a potential 10+ Bagger then load up FUM stock alreay jumping higher check it out guys


Research Confirms MED2002's US$1 Billion Potential
hxxps://futuramedical.com/content/news/archive17/060317b.asp

The latest market research further endorses Futura's strategy of developing MED2002 as a prescription product in standard and increased strength dose forms, with the objective of switching the standard dose form to an OTC product at an appropriate time.

Ipsos's validated healthcare forecasting model was used to predict peak OTC annual sales for MED2002 in key countries worldwide in excess of US$650 million. This forecast follows earlier market research commissioned into the potential of MED2002 as a prescription product, which indicated a prescription market size of up to US$600 million in key countries worldwide.

Ipsos forecasts that 70% of OTC product sales will be incremental to the prescription ED category. As a result, the estimated peak annual sales of MED2002 in prescription and OTC versions is predicted to be more than US$1 billion prior to the expiry of the product's expected patent life.

The Ipsos valuation was based on the outcomes from primary market research carried out amongst 400 men with ED or suspected ED in the USA. The respondents were in four groups: satisfied users of PDE5 inhibitors (the class of drugs such as Viagra and Cialis); dissatisfied users of PDE5 inhibitors; diagnosed but untreated ED sufferers; and suspected though undiagnosed ED sufferers. The respondents were shown a concept about MED2002 as part of the market research though they did not use the product as it is currently in clinical development.

The key findings of the market research showed that the respondents believed that the product, once approved, is highly differentiated from existing products and that its claims would meet their needs. MED2002's rapid onset of action, an average of less than five minutes, was the key feature that attracted respondents to the product and could command a price premium compared with existing ED treatments, which have a substantially slower onset of action.

The Ipsos healthcare forecasting model has been demonstrated by Ipsos to be within 20% of actual sales volumes in 9 out of 10 of its forecasts.


Pipeline
hxxps://www.futuramedical.com/media/144144/Pipeline-2018.jpg

MED2002 (topical treatment for erectile dysfunction) hxxps://futuramedical.com/content/products/med_2002.asp

first patient dosed: in Q3/Q4 2018
Last patient dosed: by end of June 2019
Headline efficacy results: by end of December 2019

CSD500: Erectogenic condom
hxxps://futuramedical.com/content/products/csd_500.asp

Significant milestone achieved with approval of 2-year shelf life approved for CSD500, the erectogenic condom in September 2018. Development now complete. Discussions are ongoing with current and potential further distribution partners on next steps with the product in a number of markets.

Pain relief products: TPR100 (diclofenac) and TIB200 (ibuprofen) hxxps://futuramedical.com/content/products/tpr_100.asp

TPR100 commercial partner Thornton & Ross filed for UK regulatory submission in July 2018.
Out-licensing discussions for TPR100 outside of the UK are ongoing.

bioking
08/1/2019
12:28
Thanks for the NXT headsup a week ago, it's doing nicely now, ticking up every day. Put 5% of SIPP on it, one happy bunny! Cheers!
cooltools
08/1/2019
11:16
Comparison starting at a gallop (of course): Lauders, Red and apad leading, in that order.

What do they say about strong starters? Hmm...... We shall see. Plenty of time left!

CKN having a good start to the year. Don't hold but always interested in how it does as it is a shipping company and gives an idea about world trade.

lauders
08/1/2019
11:15
Bought some SSON and Fundsmith global earlier. just a small step back in. re balancing really.
thelongandtheshortandthetall
08/1/2019
11:11
New Joel Greenblatt vid

always worth a watch:

thelongandtheshortandthetall
08/1/2019
09:09
ps

Both SOS and PTSG are below recent placing prices.

apad
08/1/2019
09:06
Mr. M unimpressed by ABC. Looks like my top-slicing was sensible. I wouldn't be inclined to increase until their software project has finished and margins improve. It's still the gorilla.

SOS still responding well to Scott's comments and BOO has regained its momentum ahead of next week's update.

Comparison starting at a gallop (of course): Lauders, Red and apad leading, in that order.

Malcy opines that February will be a busy month for AMER, with the CEO doing the rounds of institutions pedalling his 'good news' wares.

apad

apad
08/1/2019
07:54
Knew I should have swapped spe for ztf in the comparison

Sopheon, the international provider of software, expertise, and best practices for enterprise innovation management solutions, announces that it is partnering with global confectioner The Hershey Company (NYSE:HSY) to support digital transformation of Hershey's product innovation portfolios.

janeann
07/1/2019
19:47
Lol well it's a £2.7bn company so any stake under say £25m would be very easy to unload.
hydrus
07/1/2019
18:51
Tongue in cheek, Hydrus, but I have rather a lot of shares and if a knight in shining armour wanted to buy them all it would solve the problem of feeding them into the market.... Gulp!

apad😊

apad
07/1/2019
18:46
APAD if you want a takeover that suggests you really think you should sell. Not sure it's worth you just hanging in in the hope for maybe a 20% - 30% premium? That's a long shot anyway.
hydrus
Chat Pages: Latest  951  950  949  948  947  946  945  944  943  942  941  940  Older

Your Recent History

Delayed Upgrade Clock